TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
Sports
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | United StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
UPSC | Exam ScheduleExam Mentor
Don't Miss
Advertisement

India drops popular Zantac from essential medicine list over cancer concerns

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Aditi Tandon

Advertisement

New Delhi, September 13

Advertisement

India on Tuesday dropped antacid Ranitidine, popularly sold as Zantac, from the National List of Essential Medicines 2022 over cancer concerns.

Ranitidine is among 26 medicines dropped from the NLEM 2015 version.

Zantac and other ranitidine products contaminated with high levels of NDMA, a probable human carcinogen, could cause many types of cancer, including bladder cancer, colon cancer and prostate cancer.

Advertisement

In 2019, N-nitrosodimethylamine (NDMA) was identified in samples of ranitidine which led the US FDA to alert the public of the potential risks associated with NDMA exposure, which include cancer.

Heartburn drug Ranitidine has been extensively used in India.

It is a gastrointestinal drug.

The latest version of NLEM drops all forms of Ranitidine: 150 mg tablet, oral liquid and injection.

Vice chairman of the committee that finalised NLEM 2022 YK Gupta said deletion involves medicines banned by the regulator due to side effects and safety concerns which change the drug’s risk benefit balance.

Advertisement
Show comments
Advertisement